- Open Access
Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients
© Mikirova et al.; licensee BioMed Central Ltd. 2013
Received: 23 April 2013
Accepted: 5 June 2013
Published: 15 August 2013
Ascorbic acid (vitamin C, ascorbate) is a key water soluble antioxidant that, when administered in doses well above its recommended dietary allowance, may have preventative and therapeutic value against a number of pathologies. The intravenous administration of high dose ascorbate (IVC) has increased in popularity among complementary and alternative medicine practitioners: thousands of patients received IVC, at an average dose of 0.5 g/kg, without significant side effects. While IVC may have a variety of possible applications, it has generated the most interest for its potential use in treating cancer.
Medical records of patients with cancer treated with IVC at the Riordan Clinic were retrospectively reviewed. Cancer patients, for whom plasma ascorbate concentration data before and after treatment were available, along with C-reactive protein (CRP) measurements, were chosen for analysis.
The results of the analysis can be summarized as follows. IVC produces peak plasma ascorbate concentrations on the order of ten millimolars with lower peak plasma concentrations obtained in cancer patients as compared to healthy subjects. Cancer patients who are deficient in vitamin C prior to therapy tend to achieve lower plasma levels post infusion. High inflammation or tumor burdens, as measured by CRP or tumor antigen levels, tend to lower peak plasma ascorbate levels after IVC. When compared to patients with localized tumors, patients with metastatic tumors tend to achieve lower post infusion plasma ascorbate concentrations.
The data indicate that, while potentially therapeutic plasma ascorbate concentrations can be achieved with IVC, levels attained will vary based on tumor burden and degree of inflammation (among other factors). Evidence suggests that IVC may be able to modulate inflammation, which in turn might improve outcomes for cancer patients. IVC may serve as a safe, adjunctive therapy in clinical cancer care.
Vitamin C is an antioxidant that increases extracellular collagen production and is important for immune cell functioning [1, 2]. The intravenous administration of vitamin C involves the slow infusion of vitamin C at doses on the order of 0.1 to 1.0 grams per kilogram body mass and has become increasingly popular among complementary and alternative medicine practitioners . When vitamin C is given by intravenous infusion, peak concentrations over 10 mM, two orders of magnitude above what is observed with oral supplementation, can be attained [4, 5] without significant adverse effects to the recipient. While IVC may have a variety of possible applications, such as combating infections [6–8], treating rheumatoid arthritis , it has generated the most interest for its potential use in treating cancer.
Vitamin C can potentially help cancer patients in a variety of ways: its role in collagen production may protect normal tissue from tumor invasiveness and metastasis [10, 11], while vitamin C replenishment in cancer patients, who are often depleted of this vitamin [12, 13], may improve immune system function and enhance patient health and well-being .
The use of high doses intravenously has drawn particular interest for the following reasons:
A profound reduction of plasma ascorbate levels is observed in cancer patients [15–21]. This ascorbate deficiency (clinical scurvy) was correlated with elevated levels of the inflammation marker C-reactive protein often manifesting the shorter survival times.
At concentrations on the order of 1 mM, ascorbate can cause a build-up of hydrogen peroxide, which is preferentially toxic toward tumor cells [4, 22, 23]. Experimental studies confirm that ascorbate concentrations sufficient for this cytotoxic effect can be attained in vivo, and that treatments can reduce tumor growth in animal models [24–28].
Ascorbate, at concentrations of 1 to 10 mM, can have an inhibitory effect on tumor angiogenesis [29–34], a process of new blood vessel formation that is considered critical to tumor growth and metastasis.
Phase I clinical trials indicate that IVC can be administered safely with relatively few adverse effects [13, 35]. Clinical studies have demonstrated that IVC significantly improved global quality of life scores in cancer patients. Patients given IVC in addition to standard oncologic treatments benefited from less fatigue, reduction in nausea, improved appetite, reductions in depression and fewer sleep disorders [36, 37], and their overall intensity scores of adverse symptoms during therapy and aftercare were half those of the control (no IVC) group. Other studies report anti-cancer efficacy, improved patient well-being, and decreases in markers of inflammation and tumor growth [38–43].
The relationship between IVC dose and plasma ascorbate concentration is important in understanding the ascorbic acid’s effect on cancer. In this regard, we analyzed this relationship in a large database of cancer patients given IVC therapy; moreover, we examined the dependence of plasma ascorbate concentrations in patients with localized and metastatic tumors on C-reactive protein levels and tumor marker levels.
The biochemical assays and analysis were performed at the Riordan Clinic Laboratory. CRP concentrations in blood (serum or heparin-plasma) were determined using a particle-enhanced immune-turbidimetric assay (CRP Ultra WR Reagent kit, Genzyme) according to manufacturer’s instructions on an automated analyzer [CobasMIRA, Roche Diagnostics]. The upper boundary for the normal range was set to 1.9 mg/L. Vitamin C was measured by high-pressure liquid chromatography (HPLC) with electrochemical detection.
Measurements of tumor antigen levels were carried out by Lab Corp. For CA15-3, Ca29.29, and CA125 electrochemiluminescence immunoassays (ECLIA) were used.
The study was conducted under Institutional Review Board Approval of Riordan Clinic, Wichita, KS, USA. Demographics were limited to ensure confidentiality.
Characteristics of cancer patients from the clinic database selected for data analysis: number of subjects, sex, age range, weight range, and average ascorbate concentrations before and immediately after the first 15 gram IVC infusion
Ascorbic acid, post (mM)
Ascorbic acid, pre (mM)
Ascorbic acid, minimum pre (mM)
Chronic Lymphocytic Leukemia
The details of the Riordan IVC protocol have been described elsewhere . Briefly, new cancer patients are given a 15 gram injection for their first dose, followed by a 25 gram injection the next day. Dosage is then adjusted by the physician based on the patients’ tolerance and plasma ascorbate levels attained post infusion.
This suggests that cancer patients may need higher doses to achieve a given plasma concentration. We found that there was a weak but statistically significant correlation between the pre-treatment plasma ascorbate concentration and the post-IVC plasma concentration attained (r = 0.28, N = 193) suggesting that patients with lower vitamin C levels may see more distribution of intravenously administered ascorbate into tissues and thus attain less in plasma. When treating patients with IVC, the first treatment likely serves to replenish depleted tissue stores, if those subjects were vitamin C deficient at the beginning of the treatment. Then, in subsequent treatments, with increasing doses, higher plasma concentrations can be attained. On-going treatments serve to progressively reduce oxidative stress in cancer patients.
The data presented in Figure 3 show the tendency of lower achievable plasma levels of vitamin C at higher levels of tumor markers. Patients with higher tumor markers are likely to have higher tumor burden, higher oxidative stress and, therefore, are more likely to have lower post IVC plasma levels.
This also seems to be the case for patients with elevated inflammation, measured by CRP. Figure 4A illustrates the relationship between inflammation and ascorbate pharmacology. Data are plotted as plasma ascorbate (plasma concentration in mM divided by dose in g/kg) versus the inflammation marker CRP. Values for CRP are significant for correlation at the 95% confidence level (p < 0.05).
In addition, patients were divided into four groups based on CRP levels, and the average plasma ascorbate concentration normalized to dose (mM per g/kg) for each group was calculated (Figure 4B). The patients who showed most severe inflammation (CRP > 70 mg/L) had significantly lower plasma ascorbate levels after infusion (p < 0.01).
These pharmacokinetic data can be summarized up as follows: IVC produces peak plasma ascorbate concentrations (30–50 min after beginning of infusion) on the order of ten millimolars. Results are highly variable from patient to patient, with the following tendencies observed:
Lower peak plasma concentrations are obtained in cancer patients than in healthy subjects. Cancer patients who are deficient in vitamin C prior to therapy tend to achieve lower plasma levels post infusion.
Patients with higher inflammation or tumor burdens, as measured by CRP levels or tumor antigen levels, tend to show lower peak plasma ascorbate levels after IVC.
Patients with metastatic tumors tend to achieve lower post infusion plasma ascorbate levels than those with localized tumors.
The characteristics of patients with prostate cancer from the clinic database with values of PSA before and after treatment, number of treatments, duration of treatments and percentage of improvement
Type of cancer
Days of treatment
Number of treatments
Percentage of improvement
Gleason score - 6-9
Grade II-III; Stage B2
Gleason score 2.5
Gleason score 6
Gleason score 9
Gleason score 4
Gleason score 4
Gleason score 5
Gleason score 6
Gleason score 8
Gleason score 6
Gleason score 6-8
Gleason score 6
Gleason score 6-8
Gleason score 6.5, stage II
Relation between changes in CRP levels and changes in tumor markers (TM) after IVC therapy
Type of cancer
% of CRP change
% of TM change
Type of cancer
% of CRP change
% of TM change
Intravenous vitamin C, as administered by slow infusion, allows for plasma ascorbate concentrations an order of magnitude beyond those attainable with oral administration. Rationales for IVC therapy include preferential toxicity of ascorbate toward cancer cells [22, 45], potential benefits of ascorbate for immune cells, and ascorbate inhibitory effect on angiogenesis [32, 33]. In experiments with a guinea pig tumor model, tumor growth was significantly reduced in cases where intra-tumor ascorbate concentrations reached the millimolar level .
Vitamin C was first suggested as a tool for cancer treatment in the 1950’s: its role in collagen production and protection led scientists to hypothesize that ascorbate replenishment would protect normal tissue from tumor invasiveness and metastasis [10, 11]. Cameron and Pauling observed fourfold survival times in terminal cancer patients treated with intravenous ascorbate infusions followed by oral supplementation . However, two randomized clinical trials with oral ascorbate alone conducted by the Mayo clinic showed no benefit [55, 56]. Most research from that point on focused on intravenous ascorbate.
The present manuscript provides information on how inflammation and tumor burden can affect the peak plasma ascorbate concentration achieved via IVC therapy. Both inflammation and tumor burden are representative of the total oxidative stress load of advancing cancer that IVC can help to safely reduce.
Data presented above indicate that large doses given intravenously may result in maximum plasma concentrations of roughly 30 mM, a level that has been shown to be sufficient for preferential cytotoxicity against cancer cells . This is in contrast to the effects of oral ascorbate supplementation, as data according to study  showed that once oral intake of vitamin C exceeded 200 mg administered once daily, it was difficult to increase plasma and tissue concentrations above roughly 200 μM.
Patients with advanced or metastatic cancers demonstrate higher levels of oxidative stress and inflammation as seen in the subjects we reported in this paper. The inflammatory microenvironment of cancer cells leads to increasing oxidative stress, which apparently depletes vitamin C, resulting in lower plasma ascorbate concentrations in blood samples post IVC infusion. Another explanation for this finding may be that cancers are themselves more metabolically active in their uptake of vitamin C, causing subjects to absorb more of the vitamin, and as a results show lower plasma ascorbate concentrations in blood post IVC infusion.
The presence of metastases demonstrates an even higher demand for vitamin C due to one or the other, or perhaps both of these two explanations for low vitamin C in advancing cancer.
Many tumors in vivo appear to be under persistent oxidative stress. [61, 62]. Tumor cells may overproduce ROS because the NADPH-oxidase is regulated by the GTPase Rac1, which is itself downstream of the proto-oncogene Ras . Sub lethal oxidative stress promotes cell proliferation in vitro, with both superoxide and hydrogen peroxide stimulating growth . Proliferation in response to hydrogen peroxide may be due to the activation of mitogen-activated protein kinases (MAPKs). Oxygen radicals augment tumor cell migration, increasing the risk of invasion and metastasis, as the p38 MAPK is activated by oxidative stress , and the phosphorylation of heat shock protein-27 by p38 MAPK has been shown to induce changes in actin dynamics . These oxygen radicals may deplete vitamin C in cancer patients, and may contribute to the lower plasma ascorbate levels attained by IVC in cancer patients, compared to plasma ascorbate levels attained in healthy subjects.
The finding of decreased plasma ascorbate levels in cancer patients may relate to the molecular structure of ascorbic acid; in particular, the similarity of its oxidized form, dihydroascorbic acid, to glucose. Since tumor have increased requirement for glucose , transport of dehydroascorbate into the cancer cells via glucose transport molecules and ascorbate through sodium-dependent transporter may be elevated [68, 69]. Increased accumulation of ascorbic acid in the tumor site was supported by measurements of the level of ascorbic acid in tumors in animal experiments . Also, patients with advanced malignancies may have lower level of ascorbic acid in tissue, creating a higher demand for the vitamin C.
IVC therapy appears to reduce CRP levels in cancer patients. CRP concentrations directly correlate with disease activity in many cases and can contribute to disease progression through a range of pro-inflammatory properties. Being an exquisitely sensitive marker of systemic inflammation and tissue damage, CRP is very useful in screening for organic disease and monitoring treatment responses .
While a variety of factors can affect CRP levels, including sex, body mass index, and cardiovascular health, recent studies indicate its importance in malignant diseases. For example, increases in CRP concentrations have been associated with poorer prognosis of survival in cancer patients, particularly with advance disease independent of tumor stage . According to Figure 4 above, patients with severely elevated CRP levels attain plasma ascorbate concentrations after IVC infusions that are only 65% of those attained for subjects with normal CRP levels. More detailed analysis of patients treated by IVC with follow-up several year showed that suppression of inflammation in cancer patients by high-dose IVC is feasible and potentially beneficial . Inflammation plays a key role in tumor development, affecting tumor proliferation, angiogenesis, metastasis, and resistance to therapy [72–77]. Cancer-related inflammation accompanied by leukocyte infiltration, cytokine build-up, tissue remodeling, angiogenesis, and inflammatory microenvironment , is a key component in tumors of epithelial origins . While immune cells may repress tumor growth in some cases [80, 81], the inflammatory microenvironments within tumors can facilitate cancer development. In clinical studies, the use of anti-inflammatory agents is associated with reduced instances of certain cancers .
Inflammation is a marker of high cancer risk, and poor treatment outcome [83, 84]. The subjects with highly elevated CRP concentrations have a three-fold elevation “all-cause” mortality risk and a twenty-eight fold increase in cancer mortality risk .
The properties of ascorbic acid as antioxidant and an enhancer of immune function, as well as the correlations between ascorbate depletion in cancer patients and prognosis , suggest that vitamin C may have a beneficial effect on inflammation in cancer patients. The data presented above support this idea.
In summary, the data detailed in the present manuscript indicate that, while potentially therapeutic plasma ascorbate concentrations can be achieved with IVC, levels attained will vary based on tumor burden and degree of inflammation. Evidence suggests that IVC may be able to modulate inflammation, which in turn might improve outcomes for cancer patients. IVC may serve as a safe, adjunctive therapy in clinical cancer care.
Written informed consent was obtained from the patient for the publication of this report and any accompanying images.
The study was supported by Allan P Markin and Flossie E West Memorial Trust.
- Murad S, Grove D, Lindberg KA, Reynolds G, Sivarajah A, Pinnell SR: Regulation of collagen synthesis by ascorbic acid. Proc Natl Acad Sci USA. 1981, 78 (5): 2879-2882. 10.1073/pnas.78.5.2879.PubMed CentralView ArticlePubMedGoogle Scholar
- Ottoboni F, Ottoboni A: Ascorbic acid and the immune system. J Orthomolecular Med. 2005, 20 (3): 179-183.Google Scholar
- Padayatty SJ, Sun AY, Chen Q, Espey MG, Drisko J, Levine M: Vitamin C: intravenous use by complementary and alternative medicine practitioners and adverse effects. PLoS One. 2010, 5 (7): 11414-10.1371/journal.pone.0011414.View ArticleGoogle Scholar
- Frei B, Lawson S: Vitamin C and cancer revisited. PNAC USA. 2008, 105: 11037-11038. 10.1073/pnas.0806433105.View ArticleGoogle Scholar
- Padayatti SJ, Sun H, Wang Y, Riordan HD, Hewitt SM, Katz A, Wesley RA: Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med. 2004, 140: 533-537. 10.7326/0003-4819-140-7-200404060-00010.View ArticleGoogle Scholar
- Klenner FR: The treatment of poliomyelitis and other virus diseases with vitamin C. South Med Surg. 1949, 111: 209-214.PubMedGoogle Scholar
- Klenner FR: Massive doses of vitamin C and the virus diseases. South Med Surg. 1951, 113: 101-107.PubMedGoogle Scholar
- Calleja HB, Brooks RH: Acute hepatitis treated with high doses of vitamin C. Report of a case. Ohio Med. 1960, 56: 821-823.PubMedGoogle Scholar
- Mikirova N, Rogers A, Casciari J, Taylor P: Effects of high dose intravenous ascorbic acid on the level of inflammation in patients with rheumatoid arthritis. Mod Res Inflamm. 2012, 1: 26-32. 10.4236/mri.2012.12004.View ArticleGoogle Scholar
- McCormick W: Cancer: a collagen disease, secondary to nutrition deficiency. Arch Pediatr. 1959, 76: 166-171.PubMedGoogle Scholar
- Cameron E, Pauling L, Leibovitz B: Ascorbic acid and cancer, a review. Cancer Res. 1979, 39: 663-681.PubMedGoogle Scholar
- Hoffman F: Micronutrient requirements of cancer patients. Cancer. 1985, 55 (1): 145-150.Google Scholar
- Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda-Massari JR, Taylor P, Jackson JA: A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J. 2005, 24: 269-276.PubMedGoogle Scholar
- Henson D, Block G, Levine M: Ascorbic acid: biological functions and relation to cancer. JNCI. 1991, 83: 547-550. 10.1093/jnci/83.8.547.View ArticlePubMedGoogle Scholar
- Fain O, Mathieu E, Thomas M: Scurvy in patients with cancer. BMJ. 1998, 316: 1661-1662.PubMed CentralView ArticlePubMedGoogle Scholar
- Mayland CR, Bennett MI, Allan K: Vitamin C deficiency in cancer patients. Palliat Med. 2005, 19: 17-20. 10.1191/0269216305pm970oa.View ArticlePubMedGoogle Scholar
- Bodansky O, Wroblewski F, Markardt B: Concentrations of ascorbic acid in plasma and white blood cells of patients with cancer and noncancerous chronic disease. Cancer. 1952, 5: 678-684. 10.1002/1097-0142(195207)5:4<678::AID-CNCR2820050404>3.0.CO;2-7.View ArticlePubMedGoogle Scholar
- Butcher RG, Chayen J: Oxidation of L-ascorbic acid by cells of carcinoma of the human cervix. Nature. 1965, 207: 992-993. 10.1038/207992a0.View ArticlePubMedGoogle Scholar
- Fraenkel-Conrat J, Stoy T, Tsai SF: Investigation of ascorbic acid levels in blood of cancer patients compared to normal subjects. Mo Med. 1967, 64: 1001-1002.PubMedGoogle Scholar
- Anthony HM, Schorah CJ: Severe hypovitaminosis C in lung-cancer patients: the utilization of vitamin C in surgical repair and lymphocyte-related host resistance. Br J Cancer. 1982, 46: 354-367. 10.1038/bjc.1982.211.PubMed CentralView ArticlePubMedGoogle Scholar
- Gupta A, Bhatt ML, Misra MK: Lipid peroxidation and antioxidant status in head and neck squamous cell carcinoma patients. Oxid Med Cell Longev. 2009, 2: 68-72. 10.4161/oxim.2.2.8160.PubMed CentralView ArticlePubMedGoogle Scholar
- Casciari J, Riordan NS, Schmidt TL, Meng XL, Jackson J, Riordan H: Cytotoxicity of ascorbate, lipoic acid, and other antioxidants in hollow fibre in vitro tumours. Br J Cancer. 2001, 84 (11): 1544-1550. 10.1054/bjoc.2001.1814.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen Q, Espey MG, Krishna MC, Mitchell JB, Corpe CP, Buettner GR, Shacter E, Levine M: Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci USA. 2005, 102: 13604-13609. 10.1073/pnas.0506390102.PubMed CentralView ArticlePubMedGoogle Scholar
- Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci USA. 2008, 105: 11105-11109. 10.1073/pnas.0804226105.PubMed CentralView ArticlePubMedGoogle Scholar
- Verrax J, Calderon P: Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects. Free Radic Biol Med. 2009, 47: 32-40. 10.1016/j.freeradbiomed.2009.02.016.View ArticlePubMedGoogle Scholar
- Du J, Martin SM, Levine M, Wagner BA, Buettner GR, Wang SH, Taghiyev AF, Du C, Knudson CM, Cullen JJ: Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res. 2010, 16: 509-520. 10.1158/1078-0432.CCR-09-1713.PubMed CentralView ArticlePubMedGoogle Scholar
- Pollard HB, Levine MA, Eidelman O, Pollard M: Pharmacological ascorbic acid suppresses syngeneic tumor growth and metastases in hormone-refractory prostate cancer. In vivo. 2010, 24: 249-256.PubMedGoogle Scholar
- Pollard H, Levine M, Eidelman O, Pollard M: Pharmacological ascorbic acid supresses syngenic tumor growth and metastases in hormone-refractory prostate cancer. In Vivo. 2010, 24 (3): 249-255.PubMedGoogle Scholar
- Ashino H, Shimamura M, Nakajima M, Kawanaka S, Oikawa T, Iwaguchi T, Kawashima S: Novel function of ascorbic acid as an angiostatic factor. Angiogenesis. 2003, 6: 259-269.View ArticlePubMedGoogle Scholar
- Belin S, Kaya F, Duisit G, Giacomett S, Ciccoloni J, Fortes M: Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression. PLoS One. 2009, 4 (2): E44-View ArticleGoogle Scholar
- Page EL, Chan DA, Giaccia AJ, Levine M, Richard DE: Hypoxia-inducible factor-1 (alpha) stabilization in nonhypoxic conditions: role of oxidation and intracellular ascorbate depletion. Mol Biol Cell. 2007, 19: 86-94.View ArticlePubMedGoogle Scholar
- Mikirova N, Casciari J, Riordan N: Ascorbate inhibition of angiogenesis in aortic rings ex vivo and subcutaneous Matrigel plugs in vivo. J Angiogenesis Res. 2012, 2: 2-6.View ArticleGoogle Scholar
- Mikirova N, Ichim T, Riordan N: Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med. 2008, 6: 50-10.1186/1479-5876-6-50.PubMed CentralView ArticlePubMedGoogle Scholar
- Yeom CH, Lee G, Park JH, Yu J, Park S, Yi SY, Lee HR, Hong YS, Lee S: High dose concentration administration of ascorbic acid inhibits tumor growth in BALB/C mice implanted with sarcoma 180 cancer cells via the restriction of angiogenesis. J Transl Med. 2009, 7: 70-10.1186/1479-5876-7-70.PubMed CentralView ArticlePubMedGoogle Scholar
- Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH: Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol. 2008, 19 (12): 2095-View ArticleGoogle Scholar
- Vollbracht C, Schneider B, Leendert V, Weiss G, Auerbach L, Beuth J, Vollbracht C: Intravenous vitamin C administration improves quality of life in breast cacner patients during chemo-radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany. Vivo. 2011, 82: 983-990.Google Scholar
- Takahashi H, Mizuno H, Yanagisawa A: High-dose intravenous vitamin C improves quality of life in cancer patients. Personalized Medicine Universe 1. 2012, 49: e53-Google Scholar
- Jackson J, Riordan H, Hunninghauke R, Riordan N: High dose intravenous vitamin C and long time survival of a patient with cancer of the head and pancreas. J Ortho Med. 1995, 10: 87-88.Google Scholar
- Riordan H, Jackson J, Riordan N, Schultz M: High-dose intravenous vitamin C in the treatment of a patient with renal cell carcinoma of the kidney. J Ortho Med. 1998, 13: 72-73.Google Scholar
- Riordan N, Jackson JA, Riordan H: Intravenous vitamin C in a terminal cancer patient. J Ortho Med. 1996, 11: 80-82.Google Scholar
- Padayatty SJ, Riordan HD, Hewitt SM, Katz A, Hoffer LJ, Levine M: Intravenous vitamin C as a cancer therapy: three cases. CMAJ. 2006, 174 (7): 937-942. 10.1503/cmaj.050346.PubMed CentralView ArticlePubMedGoogle Scholar
- Mikirova N, Casciari J, Taylor P, Rogers A: Effect of high-dose intravenous vitamin C on inflammation in cancer patients. J Transl Med. 2012, 10: 189-10.1186/1479-5876-10-189.PubMed CentralView ArticlePubMedGoogle Scholar
- Drisko J, Chapman J, Hunter V: The use of antioxidants with first-line chemotherapy in two cases of ovarian cancer. Am J Coll Nutr. 2003, 22: 118-123. 10.1080/07315724.2003.10719284.View ArticleGoogle Scholar
- Riordan HD, Hunninghake RB, Riordan NH, Jackson JJ, Meng X, Taylor P, Casciari JJ, Gonzalez MJ, Miranda-Massari JR, Mora EM, Rosario N, Rivera A: Intravenous ascorbic acid: protocol for its application and use. P R Health Sci J. 2003, 22: 225-232.Google Scholar
- Riordan NH, Riordan HRD, Meng X, Li Y, Jackson JA: Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Medical hypothesis. 1995, 44: 207-213. 10.1016/0306-9877(95)90137-X.View ArticleGoogle Scholar
- Casciari JJ, Riordan HD, Mirranda-Massara JR, Gonzalez MJ: Effects of high dose ascorbate administration on L-10 tumor growth in guinea pigs. PR Health Sci J. 2005, 24: 145-150.Google Scholar
- Fujita K, Shinpo K, Yamada K, Sato K, Niimi H, Shamoto M, Nagatsu T, Takeuchi T, Umezawa H: Reduction of adriamycin toxicity by ascorbate in mice and guinea pigs. Cancer Res. 1982, 42: 309-316.PubMedGoogle Scholar
- Okunieff P, Suit H: Toxicity, radiation sensitivity modification, and combined drug effects of ascorbic acid with misonidazole in vivo on FSaII murine firbosarcomas. JNCI. 1987, 79: 377-381.PubMedGoogle Scholar
- Kurbacher CM, Wagner U, Kolster B, Andreotti PE, Krebs D, Bruckner HW: Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett. 1996, 103: 183-189. 10.1016/0304-3835(96)04212-7.View ArticlePubMedGoogle Scholar
- Taper H, Keyeux A, Roberfroid M: Potentiation of radiotherapy by nontoxic pretreatment with combined vitamins C and K3 in mice bearing solid transplantable tumor. Anticancer Res. 1996, 16: 499-503.PubMedGoogle Scholar
- Fromberg A, Gutsch D, Schulze D, Vollbracht C, Weiss G, Czubayko F, Aigner A: Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells toward cytostatic drugs. Cancer Chemother Pharmacol. 2011, 67: 1157-1166. 10.1007/s00280-010-1418-6.PubMed CentralView ArticlePubMedGoogle Scholar
- Shinozaki K, Hosokawa Y, Hazawa M, Kashiwakura I, Okumura K, Kaku T, Nakayama E: Ascorbic acid enhances radiation-induced apoptosis in an HL60 human leukemia cell line. J Ratiat Res. 2011, 52: 229-237.View ArticleGoogle Scholar
- Espey M, Chen P, Chalmers B, Drisko J, Sun AY, Levine M, Chen Q: Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med. 2011, 50: 1610-1619. 10.1016/j.freeradbiomed.2011.03.007.PubMed CentralView ArticlePubMedGoogle Scholar
- Cameron E, Pauling L: Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. PNAS USA. 1976, 73: 3685-3689. 10.1073/pnas.73.10.3685.PubMed CentralView ArticlePubMedGoogle Scholar
- Creagan ET, Moertel CG, O'Fallon JR, Schutt AJ, O'Connell MJ, Rubin J, Frytak S: Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial. N Engl J Med. 1979, 301: 687-690. 10.1056/NEJM197909273011303.View ArticlePubMedGoogle Scholar
- Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have no prior chemotherapy: a randomized double-blind comparison. N Engl J Med. 1985, 312: 137-141. 10.1056/NEJM198501173120301.View ArticlePubMedGoogle Scholar
- Simone CB, Simone NL, Simone V, Simone CB: Antioxidants and other nutrients do not inferfere with chemotherapy or radiation therapy and can increase survival, part 1. Atlern Ther Health Med. 2007, 13: 22-28.Google Scholar
- Block K, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C: Impact of antioxidant supplementaion on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer. 2008, 123: 1227-1239. 10.1002/ijc.23754.View ArticlePubMedGoogle Scholar
- Ullah MF, Bhat SH, Hussain E, Abu-Duhier F, Ahmad A, Hadi SM: Ascorbic acid in cancer chemoprevention: translational perspectives and efficacy. Current drug target. 2012, 13: 1757-1771. 10.2174/138945012804545669.View ArticleGoogle Scholar
- Levine M, Conry-Cantilena C, Wang Y, Welch RW, Washko PW, Dhariwal KR, Park JB, Lazarev A, Graumlich JF, King J, Cantilena LR: Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci USA. 1996, 93: 3704-3709. 10.1073/pnas.93.8.3704.PubMed CentralView ArticlePubMedGoogle Scholar
- Szatrowski TP, Nathan CF: Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991, 51: 794-798.PubMedGoogle Scholar
- Brown NS, Bicknell R: Hypoxia and oxidative stress in breast cancer Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001, 3: 323-327. 10.1186/bcr315.PubMed CentralView ArticlePubMedGoogle Scholar
- Sundaresan M, Yu Z-X, Ferrans VJ, Sulciner DJ, Gutkind JS, Irani K, Goldschmidt-Clermont PJ, Finkel T: Regulation of reactiveoxygen- species generation in fibroblasts by Rac1. Biochem J. 1996, 318: 379-382.PubMed CentralView ArticlePubMedGoogle Scholar
- Burdon RH: Superoxide and hydrogen peroxide in relation to mammalian cell proliferation. Free Radic Biol Med. 1995, 18: 775-794. 10.1016/0891-5849(94)00198-S.View ArticlePubMedGoogle Scholar
- Wang X, Martindale JL, Liu Y, Holbrook NJ: The cellular response to oxidative stress: influences of mitogen-activated protein kinase signalling pathways on cell survival. Biochem J. 1998, 333: 291-300.PubMed CentralView ArticlePubMedGoogle Scholar
- Huot J, Houle F, Marceau F, Landry J: Oxidative stress-induced actin reorganization mediated by the p38 mitogen-activated protein kinase/heat shock protein 27 pathway in vascular endothelial cells. Circ Res. 1997, 80: 383-392. 10.1161/01.RES.80.3.383.View ArticlePubMedGoogle Scholar
- Dakubo GD: The Warburg phenomenon and other metabolic alterations of cancer cells. In Mitochondrial genetics and cancer. 2010, Berlin Heidelberg: Springer–Verlag, 39-66.Google Scholar
- Agus DB, Vera JC, Golde DW: Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res. 1999, 59 (18): 4555-4558.PubMedGoogle Scholar
- Calvo MB, Figueroa A, Pulido EG, Campelo RG, Aparicio LA: Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol. 2010, 2010: 1-4. (article ID 205357)View ArticleGoogle Scholar
- Jennifer L, St. Sauver AV, Sarma DJ, Jacobson ME, McGree MM, Lieber CJ, Girman AN, Jacobsen SJ: Associations between C-reactive protein and benign prostatic hyperplasia/lower urinary tract symptom outcomes in a population-based cohort. Am J Epidemiol. 2009, 169: 1281-1290. 10.1093/aje/kwp085.View ArticleGoogle Scholar
- Lin ATL, Chen KK, Chung HJ, Chang SC: The significance of plasma C-reactive protein in patients with elevated serum prostate-specific antigen levels. Urological Science. 2010, 21 (2): 88-92. 10.1016/S1879-5226(10)60018-8.View ArticleGoogle Scholar
- Coussens LM, Werb Z: Inflammation and cancer. Nature. 2002, 420: 860-867. 10.1038/nature01322.PubMed CentralView ArticlePubMedGoogle Scholar
- Balkwill F, Charles KA, Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005, 7: 211-217. 10.1016/j.ccr.2005.02.013.View ArticlePubMedGoogle Scholar
- Hussain SP, Hofseth LJ, Harris CC: Radical causes of cancer. Nat Rev Cancer. 2003, 3: 276-285. 10.1038/nrc1046.View ArticlePubMedGoogle Scholar
- Bartsch H, Nair J: Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch Surg. 2006, 391: 499-510. 10.1007/s00423-006-0073-1.View ArticlePubMedGoogle Scholar
- de Visser KE, Eichten A, Coussens LM: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006, 6: 24-37. 10.1038/nrc1782.View ArticlePubMedGoogle Scholar
- Hussain SP, Harris CC: Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007, 121: 2373-2380. 10.1002/ijc.23173.View ArticlePubMedGoogle Scholar
- Haitian L, Ouyang W, Huang C: Inflammation, a key event in cancer development. Mol Cancer Res. 2006, 4: 221-233. 10.1158/1541-7786.MCR-05-0261.View ArticleGoogle Scholar
- Macarthur M, Hold GL, El-Omar EM: Inflammation and cancer. II. Role of chronic inflammation and cytokine polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol. 2004, 286: G515-G520. 10.1152/ajpgi.00475.2003.View ArticlePubMedGoogle Scholar
- Dunn G, Bruce A, Ikeda H, Old L, Schreiber R: Cancer immune-editing: from immunosurveillance to tumor escape. Nat Immunol. 2002, 3: 991-998. 10.1038/ni1102-991.View ArticlePubMedGoogle Scholar
- Brigati C, Noonan DM, Albini A, Benelli R: Tumors and inflammatory infiltrates: friends or foes?. Clin Exp Metastasis. 2002, 19: 247-258. 10.1023/A:1015587423262.View ArticlePubMedGoogle Scholar
- Roxburgh CS, McMillan DC: Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010, 6: 149-163. 10.2217/fon.09.136. ReviewView ArticlePubMedGoogle Scholar
- McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009, 12: 223-226. 10.1097/MCO.0b013e32832a7902. ReviewView ArticlePubMedGoogle Scholar
- Moore MM, Chua W, Charles KA, Clarke SJ: Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010, 87: 504-508. 10.1038/clpt.2009.254.View ArticlePubMedGoogle Scholar
- Marsik C, Kazemi-Shirazi L, Schickbauer T: C-reactive protein and all-cause mortality in large hospital-based cohort. Clin Chem. 2008, 54: 343-349. 10.1373/clinchem.2007.091959.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.